Validation of the International Myositis Assessment and Clinical Studies Group guideline on cancer risk stratification
Authors' conclusion
Our real-world study supported the accuracy of cancer risk stratification.
Study context
- Population
- Adult IIM patients fulfilling classification criteria, eight rheumatology centres in Hong Kong, 2004–2023327 females (68.3%)
- Participants
- 479 patients
- Exposure
- High vs intermediate vs standard cancer risk per IMACS guideline
- High riskn = 214
- Intermediate riskn = 238
- Outcome
- Cancer at or after IIM diagnosis
- Follow-up
- Within 3 years of IIM diagnosis
Methodological detailslongitudinal observational cohort, multicentre (eight rheumatology centres)
- Longitudinal observational cohort
- Multicentre (eight rheumatology centres)
Main finding
As reported in the abstract
Cancer within 3 years of IIM diagnosis
High risk vs Intermediate risk: P < 0.001 · High risk vs Standard risk: P = 0.009
- Cancer within 3 years, all patients
- 60 (12.5%)
Observational data: associations, not effects.
Further findings
Top three cancers
- Nasopharyngeal
- 25%
- Lung
- 21.1%
- Breast
- 10.5%
Risk factors for cancer
- Older age, OR
- 1.048 (1.019-1.078) (95% CI)
- Gottron's rash, OR
- 2.453 (1.123-5.356) (95% CI)
- Absence of ILD, OR
- 2.695 (1.154-6.295) (95% CI)
- Anti-TIF1g positivity, OR
- 4.627 (2.046-10.461) (95% CI)
- Anti-SAE1 positivity, OR
- 5.325 (1.271-22.300) (95% CI)
Original publication
Validation of the International Myositis Assessment and Clinical Studies Group guideline on cancer risk stratification. Rheumatology (Oxford). Published 16 September 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →